Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 8

Results For "non"

1223 News Found

Evonik launches MaxiPure Polysorbate 80 for injectable drug formulations
News | September 25, 2025

Evonik launches MaxiPure Polysorbate 80 for injectable drug formulations

Ultra-high purity surfactant for biologics and parenteral drug formulations


AstraZeneca’s Koselugo recommended for approval in the EU for Neurofibromatosis type 1
Drug Approval | September 24, 2025

AstraZeneca’s Koselugo recommended for approval in the EU for Neurofibromatosis type 1

The positive opinion is based on results from KOMET, the largest and only placebo-controlled, double-blind global Phase III trial in this patient population


Glenmark signs cancer drug licensing deal with Hengrui Pharma for $18 million upfront payment
News | September 24, 2025

Glenmark signs cancer drug licensing deal with Hengrui Pharma for $18 million upfront payment

Hengrui is eligible to receive regulatory and commercial milestone payments of up to US$1.093 billion


Lunit and Agilent collaborate to develop AI-powered diagnostic solutions for precision medicine
Digitisation | September 24, 2025

Lunit and Agilent collaborate to develop AI-powered diagnostic solutions for precision medicine

Collaboration combines Lunit's AI expertise with Agilent's diagnostic leadership to revolutionize biomarker testing and enhance precision medicine capabilities


ProBioGen to spearhead GMP manufacturing at Berlin’s gene & cell therapy hub
News | September 17, 2025

ProBioGen to spearhead GMP manufacturing at Berlin’s gene & cell therapy hub

ProBioGen will oversee the design, construction, and operation of the 4,600-square-meter GMP manufacturing unit


Rona submits IND for GalNAc-conjugated siRNA targeting obesity
Drug Approval | September 16, 2025

Rona submits IND for GalNAc-conjugated siRNA targeting obesity

RN3161 is engineered to reduce fat while preserving lean mass, setting it apart from current treatment options


Libtayo plus chemotherapy demonstrates five-year survival benefit in advanced NSCLC
Diagnostic Center | September 16, 2025

Libtayo plus chemotherapy demonstrates five-year survival benefit in advanced NSCLC

Late-breaking data presented at WCLC highlight significant and sustained improvements in overall survival, including more than doubling five-year survival rates compared to chemotherapy alone